Published in J Am Coll Cardiol on August 16, 2005
Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials (2009) 2.41
Dermal filler injection: a novel approach for limiting infarct expansion. Ann Thorac Surg (2009) 2.03
Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc Natl Acad Sci U S A (2010) 1.87
Theoretic impact of infarct compliance on left ventricular function. Ann Thorac Surg (2009) 1.75
Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc (2009) 1.62
Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol (2012) 1.60
Targeting survival pathways to create infarct-spanning bridges of human embryonic stem cell-derived cardiomyocytes. J Thorac Cardiovasc Surg (2014) 1.44
Efficacy of polymer injection for ischemic mitral regurgitation: persistent reduction of mitral regurgitation and attenuation of left ventricular remodeling. JACC Cardiovasc Interv (2015) 1.40
Intra-myocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges. Acta Biomater (2010) 1.33
Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol (2012) 1.31
Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices. J Cardiovasc Transl Res (2010) 1.28
Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials (2010) 1.15
Model-based design of mechanical therapies for myocardial infarction. J Cardiovasc Transl Res (2010) 1.11
Injectable cardiac tissue engineering for the treatment of myocardial infarction. J Cell Mol Med (2010) 1.08
Influence of injectable hyaluronic acid hydrogel degradation behavior on infarction-induced ventricular remodeling. Biomacromolecules (2011) 1.08
Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction. PLoS One (2011) 1.06
Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor. Acta Biomater (2012) 1.05
Biomimetic matrices for myocardial stabilization and stem cell transplantation. J Biomed Mater Res A (2010) 1.00
Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application. J Cell Mol Med (2010) 1.00
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
Modulation of material properties of a decellularized myocardial matrix scaffold. Macromol Biosci (2011) 0.97
Improving survival and efficacy of pluripotent stem cell-derived cardiac grafts. J Cell Mol Med (2013) 0.96
Infarct restraint to limit adverse ventricular remodeling. J Cardiovasc Transl Res (2010) 0.96
Delivering stem cells to the heart in a collagen matrix reduces relocation of cells to other organs as assessed by nanoparticle technology. Regen Med (2009) 0.95
Intramyocardial injection of platelet gel promotes endogenous repair and augments cardiac function in rats with myocardial infarction. J Am Coll Cardiol (2012) 0.95
Drug releasing systems in cardiovascular tissue engineering. J Cell Mol Med (2009) 0.95
Anisotropic reinforcement of acute anteroapical infarcts improves pump function. Circ Heart Fail (2012) 0.94
Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure. JACC Heart Fail (2013) 0.92
A novel approach for reducing ischemic mitral regurgitation by injection of a polymer to reverse remodel and reposition displaced papillary muscles. Circulation (2008) 0.85
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Calcium-alginate hydrogel-encapsulated fibroblasts provide sustained release of vascular endothelial growth factor. Tissue Eng Part A (2012) 0.83
Embryonic stem cell-based cardiopatches improve cardiac function in infarcted rats. Stem Cells Transl Med (2012) 0.82
Strategies for the chemical and biological functionalization of scaffolds for cardiac tissue engineering: a review. J R Soc Interface (2015) 0.82
Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways. Circulation (2011) 0.82
Intramyocardial delivery of VEGF165 via a novel biodegradable hydrogel induces angiogenesis and improves cardiac function after rat myocardial infarction. Heart Vessels (2015) 0.81
Injectable Hydrogels for Cardiac Tissue Repair after Myocardial Infarction. Adv Sci (Weinh) (2015) 0.81
Localized targeting of biomaterials following myocardial infarction: a foundation to build on. Trends Cardiovasc Med (2013) 0.80
Polymer injection therapy to reverse remodel the papillary muscles: efficacy in reducing mitral regurgitation in a chronic ischemic model. Circ Cardiovasc Interv (2010) 0.79
Synthetic matrices to serve as niches for muscle cell transplantation. Cells Tissues Organs (2011) 0.79
Physiological Implications of Myocardial Scar Structure. Compr Physiol (2015) 0.78
Oxime cross-linked injectable hydrogels for catheter delivery. Adv Mater (2013) 0.78
Why Is Infarct Expansion Such an Elusive Therapeutic Target? J Cardiovasc Transl Res (2015) 0.78
Transplantation Effectiveness of Induced Pluripotent Stem Cells Is Improved by a Fibrinogen Biomatrix in an Experimental Model of Ischemic Heart Failure. Tissue Eng Part A (2015) 0.77
Structural composition of myocardial infarction scar in middle-aged male and female rats: does sex matter? J Histochem Cytochem (2013) 0.77
Minimally invasive cell-seeded biomaterial systems for injectable/epicardial implantation in ischemic heart disease. Int J Nanomedicine (2012) 0.77
The use of a novel cardiac bioreactor system in investigating fibroblast physiology and its perspectives. Organogenesis (2013) 0.76
Post-infarct biomaterials, left ventricular remodeling, and heart failure: is good good enough? Congest Heart Fail (2012) 0.76
Improving Cell Engraftment in Cardiac Stem Cell Therapy. Stem Cells Int (2015) 0.76
A novel cardiac muscle-derived biomaterial reduces dyskinesia and postinfarct left ventricular remodeling in a mouse model of myocardial infarction. Physiol Rep (2015) 0.76
Timing effect of intramyocardial hydrogel injection for positively impacting left ventricular remodeling after myocardial infarction. Biomaterials (2015) 0.76
Functional Effects of Delivering Human Mesenchymal Stem Cell-Seeded Biological Sutures to an Infarcted Heart. Biores Open Access (2016) 0.75
Carbon Nanohorns Promote Maturation of Neonatal Rat Ventricular Myocytes and Inhibit Proliferation of Cardiac Fibroblasts: a Promising Scaffold for Cardiac Tissue Engineering. Nanoscale Res Lett (2016) 0.75
Understanding greater cardiomyocyte functions on aligned compared to random carbon nanofibers in PLGA. Int J Nanomedicine (2014) 0.75
Generation and Assessment of Functional Biomaterial Scaffolds for Applications in Cardiovascular Tissue Engineering and Regenerative Medicine. Adv Healthc Mater (2015) 0.75
An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats. Int J Cardiol (2016) 0.75
Intramyocardial injection of hydrogel with high interstitial spread does not impact action potential propagation. Acta Biomater (2015) 0.75
Myocardial Tissue Engineering for Regenerative Applications. Curr Cardiol Rep (2017) 0.75
Intramyocardial delivery of bFGF with a biodegradable and thermosensitive hydrogel improves angiogenesis and cardio-protection in infarcted myocardium. Exp Ther Med (2017) 0.75
Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation (2003) 5.20
Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation (2005) 4.03
Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol (2002) 3.79
The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc (2012) 3.45
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol (2005) 3.15
Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2012) 2.78
No-reflow phenomenon. Circulation (2002) 2.30
Cardiovascular effects of cocaine. Circulation (2010) 2.05
Air pollution and cardiovascular injury epidemiology, toxicology, and mechanisms. J Am Coll Cardiol (2008) 2.02
Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation (2011) 1.99
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol (2005) 1.83
Cardiovascular effects of ambient particulate air pollution exposure. Circulation (2010) 1.67
Comparison of automated oscillometric versus auscultatory blood pressure measurement. Am J Cardiol (2010) 1.66
New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation (2011) 1.66
Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart J (2012) 1.65
AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension (2003) 1.57
The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med (2006) 1.53
Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev (2011) 1.49
Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. Cardiovasc Res (2005) 1.48
Diesel exhaust exposure induces angiogenesis. Toxicol Lett (2009) 1.48
Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res (2003) 1.47
The "no-reflow" phenomenon: basic science and clinical correlates. Heart (2002) 1.46
The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol (2005) 1.46
Transplantation of neonatal cardiomyocytes after permanent coronary artery occlusion increases regional blood flow of infarcted myocardium. J Mol Cell Cardiol (2003) 1.46
The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens (Greenwich) (2003) 1.44
High-risk percutaneous coronary intervention with the TandemHeart and Impella devices: a single-center experience. J Invasive Cardiol (2011) 1.43
Clinical cardiology: physician update: erectile dysfunction and cardiovascular disease. Circulation (2011) 1.39
Rotational atherectomy in the drug-eluting stent era: a single-center experience. J Invasive Cardiol (2011) 1.38
Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol (2011) 1.37
Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol (2008) 1.35
Mechanisms of alcoholic heart disease. Ther Adv Cardiovasc Dis (2008) 1.33
The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol (2006) 1.32
Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation (2002) 1.32
Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol (2009) 1.29
Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol (2005) 1.29
A 4-year update on the safety of sildenafil citrate (Viagra). Urology (2002) 1.28
Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv (2008) 1.24
Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. J Mol Cell Cardiol (2007) 1.23
Coronary no-flow and ventricular tachycardia associated with habitual marijuana use. Ann Emerg Med (2003) 1.22
Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarction. Cardiovasc Res (2003) 1.20
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation (2003) 1.16
An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol (2012) 1.16
Early life exposure to air pollution: how bad is it? Toxicol Lett (2012) 1.16
Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. J Endocrinol (2007) 1.14
Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol (2012) 1.13
Coronary no reflow. J Mol Cell Cardiol (2011) 1.12
Direct and indirect effects of particulate matter on the cardiovascular system. Toxicol Lett (2011) 1.11
Review of vascular closure devices. J Invasive Cardiol (2010) 1.11
Measurement of Cardiac Mechanical Function in Isolated Ventricular Myocytes from Rats and Mice by Computerized Video-Based Imaging. Biol Proced Online (2001) 1.10
Role of a paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regen Med (2007) 1.08
Cytoskeletal remodeling of desmin is a more accurate measure of cardiac dysfunction than fibrosis or myocyte hypertrophy. Life Sci (2008) 1.06
Myocardial dysfunction in an animal model of cancer cachexia. Life Sci (2010) 1.04
Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol (2005) 1.04
IGF-I attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes. Am J Physiol Endocrinol Metab (2002) 1.03
Sporting events affect spectators' cardiovascular mortality: it is not just a game. Am J Med (2010) 1.03
Herbal and traditional Chinese medicine for the treatment of cardiovascular complications in diabetes mellitus. Curr Diabetes Rev (2008) 1.02
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2009) 1.02
Systemic maternal inflammation and neonatal hyperoxia induces remodeling and left ventricular dysfunction in mice. PLoS One (2011) 1.02
No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation (2003) 1.00
Long-term outcome of fetal cell transplantation on postinfarction ventricular remodeling and function. J Mol Cell Cardiol (2003) 1.00
Cellular cardiomyoplasty of cardiac fibroblasts by adenoviral delivery of MyoD ex vivo: an unlimited source of cells for myocardial repair. Circulation (2002) 0.99
Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment. Life Sci (2008) 0.99
Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol (2002) 0.99
Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol (2002) 0.99
Innovation in basic science: stem cells and their role in the treatment of paediatric cardiac failure--opportunities and challenges. Cardiol Young (2009) 0.98
Critical role of nuclear calcium/calmodulin-dependent protein kinase IIdeltaB in cardiomyocyte survival in cardiomyopathy. J Biol Chem (2009) 0.98
Peripheral chronic total occlusions treated with subintimal angioplasty and a true lumen re-entry device. J Invasive Cardiol (2009) 0.98
No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol (2010) 0.97
Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk. J Urol (2013) 0.97
Cocaine-induced acute myocardial infarction. Clin Med Res (2007) 0.96
Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc (2013) 0.96
Delivering stem cells to the heart in a collagen matrix reduces relocation of cells to other organs as assessed by nanoparticle technology. Regen Med (2009) 0.95
Transthoracic echocardiography in rats. Evalution of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar rats during aging. Basic Res Cardiol (2003) 0.95
Sildenafil in patients with cardiovascular disease. Am J Cardiol (2003) 0.93
Real-time intravascular shear stress in the rabbit abdominal aorta. IEEE Trans Biomed Eng (2009) 0.93
Cardioprotection of insulin-like growth factor-1 during reperfusion therapy: what is the underlying mechanism or mechanisms? Circ Cardiovasc Interv (2011) 0.93
Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation (2010) 0.93
Particulate air pollution and coronary heart disease. Curr Opin Cardiol (2009) 0.93
Particulate matter exposure exacerbates high glucose-induced cardiomyocyte dysfunction through ROS generation. PLoS One (2011) 0.92
Cellular cardiomyoplasty--cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure? Cardiovasc Res (2003) 0.92
Ischemic preconditioning maintains cardioprotection in aging normotensive and spontaneously hypertensive rats. Exp Gerontol (2009) 0.92
Mild hypothermia as a cardioprotective approach for acute myocardial infarction: laboratory to clinical application. J Cardiovasc Pharmacol Ther (2010) 0.92
The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts. Cardiovasc Pathol (2002) 0.92
Cardiovascular mortality in New York City after September 11, 2001. Am J Cardiol (2003) 0.92
Genetically Engineered Mesenchymal Stem Cells Influence Gene Expression in Donor Cardiomyocytes and the Recipient Heart. J Stem Cell Res Ther (2012) 0.92
Postconditioning does not reduce myocardial infarct size in an in vivo regional ischemia rodent model. J Cardiovasc Pharmacol Ther (2007) 0.91
The "Merry Christmas Coronary" and "Happy New Year Heart Attack" phenomenon. Circulation (2004) 0.91
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol (2005) 0.91
In vivo and in vitro models to test the hypothesis of particle-induced effects on cardiac function and arrhythmias. Cardiovasc Toxicol (2006) 0.91